Articles By Wayne Koberstein, Executive Editor
-
Companies To Watch: Antiva Biosciences2/27/2024
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
-
Companies to Watch: Promontory Therapeutics2/1/2024
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
-
Empress Builds Base for Small-Molecule Innovation2/1/2024
Empress, launched by Flagship Pioneering, aims to harness AI and evolutionary biology to design the next generation of small molecule therapies.
-
Neurvati Maps Path To Neuroscience Approvals1/1/2024
Can a nested financial model help bring the next generation of neuroscience treatments to patients?
-
Companies To Watch: KeifeRx1/1/2024
Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
-
Biopharma’s Eminent Challenges In 2024 — Inside & Out12/1/2023
A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.
-
Heading Back Home To The Heart11/1/2023
Cardior Pharmaceuticals, led by CEO and cofounder Claudia Ulbrich, is developing what may be a much broader approach to heart failure, one that seeks to restore the diseased heart to its natural healthy state.
-
Companies To Watch: Freya Biosciences11/1/2023
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
-
Rescuing A Company’s Core Purpose10/2/2023
When Dr. Scott Braunstein moved from his position as chairman of the board and interim CEO to become permanent CEO of Marinus Pharmaceuticals in August 2019, he had already concluded an overbroad focus was holding the company back.
-
Companies To Watch: Spruce Biosciences10/2/2023
Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.
-
Companies To Watch: Nido Biosciences9/1/2023
See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.
-
To America, A New Biopharma Model9/1/2023
Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.
-
Companies To Watch: Ventoux Biosciences8/1/2023
Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.
-
Going European — Affimed’s American CBO8/1/2023
Taking the CBO position at Affimed offered Denise Mueller a way to apply her skills in an international biotech startup environment, where she could help shape the company’s innovative approach to cancer immunotherapy.